On the ‘micro’-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action
暂无分享,去创建一个
[1] S. Charlton,et al. ‘Partial’ competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models , 2015, British journal of pharmacology.
[2] M. H. Santana,et al. Receptor-mediated biological responses are prolonged using hydrophobized ligands. , 2004, Biosensors & bioelectronics.
[3] G. Anderson. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. , 1993, Life sciences.
[4] Anatoly B Kolomeisky,et al. Physics of protein-DNA interactions: mechanisms of facilitated target search. , 2011, Physical chemistry chemical physics : PCCP.
[5] D. Swinney. Can Binding Kinetics Translate to a Clinically Differentiated Drug? From Theory to Practice , 2006 .
[6] G. Vauquelin. Determination of drug–receptor residence times by radioligand binding and functional assays: experimental strategies and physiological relevance , 2012 .
[7] R. Schwyzer. 100 Years lock‐and‐key concept: Are peptide keys shaped and guided to their receptors by the target cell membrane? , 1995, Biopolymers.
[8] G. Vauquelin,et al. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor , 2007, British journal of pharmacology.
[9] G. Vauquelin,et al. Estimation of the dissociation rate of unlabelled ligand–receptor complexes by a ‘two‐step’ competition binding approach , 2010, British journal of pharmacology.
[10] Adriaan P IJzerman,et al. Drug‐Target Residence Time—A Case for G Protein‐Coupled Receptors , 2014, Medicinal research reviews.
[11] G. Vauquelin,et al. Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands , 2014, Fundamental & clinical pharmacology.
[12] E. Garvey. Structural Mechanisms of Slow-Onset, Two-Step Enzyme Inhibition , 2010 .
[13] G. Dahl,et al. Pharmacokinetics and the drug-target residence time concept. , 2013, Drug discovery today.
[14] D. Sargent,et al. Membrane lipid phase as catalyst for peptide-receptor interactions. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[15] D C Swinney,et al. Phenotypic vs. Target‐Based Drug Discovery for First‐in‐Class Medicines , 2013, Clinical pharmacology and therapeutics.
[16] P. Morsing,et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. , 1999, Hypertension.
[17] Tod D Romo,et al. A Lipid Pathway for Ligand Binding Is Necessary for a Cannabinoid G Protein-coupled Receptor* , 2010, The Journal of Biological Chemistry.
[18] Jianfeng Pei,et al. A comprehensive analysis of the influence of drug binding kinetics on drug action at molecular and systems levels. , 2013, Molecular bioSystems.
[19] U. Holzgrabe,et al. Rational design of dualsteric GPCR ligands: quests and promise , 2010, British journal of pharmacology.
[20] P. Leff,et al. The two-state model of receptor activation. , 1995, Trends in pharmacological sciences.
[21] W. Sadee,et al. [3H]diprenorphine receptor binding in vivo and in vitro. , 1982, European journal of pharmacology.
[22] T. Kenakin,et al. Determining the Potency and Molecular Mechanism of Action of Insurmountable Antagonists , 2006, Journal of Pharmacology and Experimental Therapeutics.
[23] G. Vauquelin. Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time , 2010, Expert opinion on drug discovery.
[24] D. Swinney. The role of binding kinetics in therapeutically useful drug action. , 2009, Current opinion in drug discovery & development.
[25] G. Vauquelin,et al. Sartan–AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism , 2009, Molecular and Cellular Endocrinology.
[26] Susan M Abdel-Rahman,et al. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. , 2004, Annual review of pharmacology and toxicology.
[27] M. Johnson. Beta2-adrenoceptors: mechanisms of action of beta2-agonists. , 2001, Paediatric respiratory reviews.
[28] Dieter M. Tourlousse,et al. Effect of saponin and filipin on antagonist binding to AT 1 receptors in intact cells. , 2004, Biochemical pharmacology.
[29] Hartmut Derendorf,et al. Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development , 2000, Journal of clinical pharmacology.
[30] T. Mavromoustakos,et al. Comparative biophysical studies of sartan class drug molecules losartan and candesartan (CV-11974) with membrane bilayers. , 2011, The journal of physical chemistry. B.
[31] N. Volkow,et al. Evaluation of the importance of rebinding to receptors in slowing the approach to equilibrium of high‐affinity PET and SPECT radiotracers , 1998, Synapse.
[32] Arthur Christopoulos,et al. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology , 2003, Pharmacological Reviews.
[33] M. Castanho,et al. Lipid membrane-induced optimization for ligand–receptor docking: recent tools and insights for the “membrane catalysis” model , 2005, European Biophysics Journal.
[34] George E. P. Box,et al. Evolutionary Operation: A Statistical Method for Process Improvement , 1969 .
[35] L B Sheiner,et al. Kinetics of pharmacologic response. , 1982, Pharmacology & therapeutics.
[36] S. Charlton,et al. Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands , 2013, British journal of pharmacology.
[37] L. Herbette. Membrane pathways for drug/ion channel interactions: Molecular basis for pharmacokinetic properties , 1994 .
[38] J. Biollaz,et al. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. , 1995, Hypertension.
[39] M. Dembo,et al. Approximating the effects of diffusion on reversible reactions at the cell surface: ligand-receptor kinetics. , 1995, Biophysical journal.
[40] Robert A Copeland,et al. The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety , 2010, Expert opinion on drug discovery.
[41] H R Hoogenboom,et al. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. , 2001, Journal of immunological methods.
[42] G. Vauquelin. Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time , 2013, Naunyn-Schmiedeberg's Archives of Pharmacology.
[43] Oliver P. Ernst,et al. A Ligand Channel through the G Protein Coupled Receptor Opsin , 2009, PloS one.
[44] G. Vauquelin,et al. Molecular mechanisms for the persistent bronchodilatory effect of the β2‐adrenoceptor agonist salmeterol , 2009, British journal of pharmacology.
[45] A. Vasudevan,et al. Design strategies to address kinetics of drug binding and residence time. , 2015, Bioorganic & medicinal chemistry letters.
[46] A. IJzerman,et al. Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor , 2014, British journal of pharmacology.
[47] V. Massey,et al. Determination of dissociation constants and specific rate constants of enzyme-substrate (or protein-ligand) interactions from rapid reaction kinetic data. , 1975, The Journal of biological chemistry.
[48] G. Vauquelin,et al. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding. , 1999, European journal of pharmacology.
[49] M. Johnson,et al. Stable activation and desensitization of beta 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite. , 1996, Molecular pharmacology.
[50] G. Vauquelin,et al. Ligands, their receptors and … plasma membranes , 2009, Molecular and Cellular Endocrinology.
[51] G. Vauquelin,et al. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists. , 2001, Biochemical pharmacology.
[52] S. Charlton,et al. Slow receptor dissociation is not a key factor in the duration of action of inhaled long‐acting β2‐adrenoceptor agonists , 2012, British journal of pharmacology.
[53] K. Kubo,et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. , 1997, European journal of pharmacology.
[54] M. Eigen. Diffusion Control in Biochemical Reactions , 1974 .
[55] M. Lohse,et al. Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[56] R. Kramer,et al. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers , 1998, Nature.
[57] John Reilly,et al. Observed Drug-Receptor Association Rates Are Governed by Membrane Affinity: The Importance of Establishing “Micro-Pharmacokinetic/Pharmacodynamic Relationships” at the β2-Adrenoceptor , 2014, Molecular Pharmacology.
[58] G. Vauquelin,et al. Radioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems , 2012, Expert opinion on drug discovery.
[59] B. Goldstein,et al. Effects of the geometry of the immunological synapse on the delivery of effector molecules. , 2004, Biophysical journal.
[60] S. Hoare. Allosteric Modulators of Class B G-Protein-Coupled Receptors , 2007, Current neuropharmacology.
[61] Rocha e Silva. A thermodynamic approach to problems of drug antagonism I. The "Charnière theory". , 1969, European Journal of Pharmacology.
[62] J. Jakubík,et al. Role of Receptor Protein and Membrane Lipids in Xanomeline Wash-Resistant Binding to Muscarinic M1 Receptors , 2004, Journal of Pharmacology and Experimental Therapeutics.
[63] R. Shrager,et al. Diffusion delays and unstirred layer effects at monolayer cultures of Chinese hamster ovary cells , 2006, Cell Biochemistry and Biophysics.
[64] S. Widmayer,et al. Quantum Statistical Mechanics in the Natural Sciences , 1974, Studies in the Natural Sciences.
[65] S. Green,et al. Sustained Activation of a G Protein-coupled Receptor via “Anchored” Agonist Binding , 1996, The Journal of Biological Chemistry.
[66] M. Johnson,et al. Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists. , 1996, Trends in pharmacological sciences.
[67] D. Myszka,et al. Probing the mechanism of drug/lipid membrane interactions using Biacore. , 2004, Analytical biochemistry.
[68] Arthur Christopoulos,et al. Bridging the gap: bitopic ligands of G-protein-coupled receptors. , 2013, Trends in pharmacological sciences.
[69] Hugh Rosen,et al. Crystal Structure of a Lipid G Protein–Coupled Receptor , 2012, Science.
[70] D. Rhodes,et al. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. , 1991, Journal of medicinal chemistry.
[71] D. Swinney,et al. How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.
[72] N. Birdsall,et al. Modification of the binding properties of muscarinic receptors by gallamine. , 1983, Molecular pharmacology.
[73] D. Swinney,et al. A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands , 2014, British journal of pharmacology.
[74] P. Sexton,et al. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. , 2012, Annual review of pharmacology and toxicology.
[75] George M Whitesides,et al. Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. , 1998, Angewandte Chemie.
[76] M. Trevethick,et al. The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor. , 2011, Pulmonary pharmacology & therapeutics.
[77] R. Copeland,et al. Residence time of receptor-ligand complexes and its effect on biological function. , 2008, Biochemistry.
[78] P. Hudson,et al. Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.
[79] D. Swinney,et al. Biochemical mechanisms of drug action: what does it take for success? , 2004, Nature Reviews Drug Discovery.
[80] G. Vauquelin,et al. Binding of the antagonist []candesartan to angiotensin II AT1 receptor-tranfected Chinese hamster ovary cells , 1999 .
[81] G. Vauquelin,et al. Slow antagonist dissociation and long-lasting in vivo receptor protection. , 2006, Trends in pharmacological sciences.
[82] P. Molinoff,et al. Fundamental difference between the molecular interactions of agonists and antagonists with the β-adrenergic receptor , 1979, Nature.
[83] Terry Kenakin,et al. Ligand-selective receptor conformations revisited: the promise and the problem. , 2003, Trends in pharmacological sciences.
[84] S. Charlton,et al. Long‐lasting target binding and rebinding as mechanisms to prolong in vivo drug action , 2010, British journal of pharmacology.
[85] Frederick Monsma,et al. The importance of drug-target residence time. , 2009, Current opinion in drug discovery & development.
[86] R. Mansi,et al. Hybrid bombesin analogues: combining an agonist and an antagonist in defined distances for optimized tumor targeting. , 2013, Journal of the American Chemical Society.
[87] G. Müller,et al. Mapping of ligand binding sites of the cholecystokinin-B/gastrin receptor with lipo-gastrin peptides and molecular modeling. , 1997, Biopolymers.
[88] A. Plückthun,et al. New protein engineering approaches to multivalent and bispecific antibody fragments. , 1997, Immunotechnology : an international journal of immunological engineering.
[89] G. Vauquelin,et al. Models and methods for studying insurmountable antagonism. , 2002, Trends in pharmacological sciences.
[90] G. Vauquelin,et al. Distinct binding properties of the AT(1) receptor antagonist [(3)H]candesartan to intact cells and membrane preparations. , 2002, Biochemical pharmacology.
[91] G. Adams,et al. Affinity and avidity in antibody-based tumor targeting. , 2009, Cancer biotherapy & radiopharmaceuticals.
[92] P. Tonge,et al. Drug-target residence time: critical information for lead optimization. , 2010, Current opinion in chemical biology.
[93] Jennifer Venhorst,et al. Target-drug interactions: first principles and their application to drug discovery. , 2012, Drug discovery today.
[94] R. Austin,et al. QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonists. , 2003, Journal of medicinal chemistry.
[95] Albert C. Pan,et al. Pathway and mechanism of drug binding to G-protein-coupled receptors , 2011, Proceedings of the National Academy of Sciences.
[96] T. Kenakin. Cellular assays as portals to seven-transmembrane receptor-based drug discovery , 2009, Nature Reviews Drug Discovery.
[97] T. Kenakin,et al. G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.
[98] M. Poo,et al. Rates of membrane-associated reactions: reduction of dimensionality revisited , 1986, The Journal of cell biology.
[99] R. Copeland. Conformational adaptation in drug-target interactions and residence time. , 2011, Future medicinal chemistry.